Living Cell Technologies Ltd
Suite 2.11 / 737 Burwood Rd
Hawthorn VIC 3122
ABN: 14 104 028 042

Quarterly Cash Flow Report Period Ended 30 September 2005

27 October 2005

Attached is the 4C – Quarterly Cash Flow Report – for Living Cell Technologies (ASX:LCT) for the quarter ended 30 September 2005.

The cash flow results are in line with management's expectations and reflect a number of initiatives involved in the company's product development over the past quarter.

During the quarter, LCT has been preparing Investigational New Drug (IND) applications for human clinical trials and finalising pre-clinical primate studies for both its lead products, NeurotrophinCell and DiabeCell.

LCT continues to make good progress with the announcement of a joint venture with leading US stem cell developer MultiCell Technologies. The company also recently announced it had filed a request for a Pre-IND meeting with the FDA to seek guidance and feedback on the development program for its NeurotrophinCell product.

The cash balance at the end of the quarter to 30 September 2005 was $3,261,703 compared to $2,648,491 at the end of the quarter to 30 June 2005, a net increase in cash of $613,212.

During the quarter LCT successfully raised $2,342,903 through a placement of ordinary shares to existing shareholders. The funds raised will be used to accelerate the regulatory applications of LCT's lead cell therapy products.

Total operating and investing cash flows for the three month period were $1,641,390 compared to $1,633,186 in the preceding three months. This reflects the continued close monitoring of cash utilization which is also apparent in the net operating cash flows for the September quarter, at $1,549,641 compared to $1,478,915 in the June quarter.

Upcoming event:

- LCT Annual General Meeting
- Wednesday 16 November (4:30pm AEST)
- NSW Trade and Investment Centre - Level 44, 225 George St, Sydney.

Further information:	
Richard Justice Chief Financial Officer Tel: +64 9 276 2690 rjustice@lctglobal.com	Paris Brooke General Manager – LCT Tel: +61 3 9813 5501 pbrooke@lctglobal.com

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies Ltd (ASX: LCT) develops live cell therapy products to treat life threatening human diseases. The ASX listed, vertically integrated company operates globally through offices in Australia, New Zealand and the United States. The company's product portfolio focuses on treatments for Huntington's disease, insulin-dependent diabetes and haemophilia.

Rule 4.7B

Appendix 4C

Quarterly report
for entities admitted
on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Living Cell Technologies Limited

ABN	Quarter ended ("current quarter")
14 104 028 042	30 September 2005

Consolidated statement of cash flows

	Cash flows related to operating activities	Current quarter $A	Year to date (.3..months) $A
1.1	Receipts from customers	34,638	34,638
1.2	Payments for (a) staff costs	(141,411)	(141,411)
	(b) advertising and marketing	(4,918)	(4,918)
	(c) research and development	(713,246)	(713,246)
	(d) leased assets	-	-
	(e) other working capital	(755,195)	(755,195)
1.3	Dividends received	75	75
1.4	Interest and other items of a similar nature received	30,416	30,416
1.5	Interest and other costs of finance paid		
1.6	Income taxes paid		
1.7	Other (provide details if material)		
	Net operating cash flows	(1,549,641)	(1,549,641)

+ See chapter 19 for defined terms.

		Current quarter $A	Year to date (.3...months) $A
1.8	Net operating cash flows (carried forward)	(1,549,641)	(1,549,641)
	Cash flows related to investing activities		
1.9	Payment for acquisition of:		
	(a) businesses (item 5)		
	(b) equity investments		
	(c) intellectual property		
	(d) physical non-current assets	(91,749)	(91,749)
	(e) other non-current assets		
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)		
	(b) equity investments		
	(c) intellectual property		
	(d) physical non-current assets		
	(e) other non-current assets		
1.11	Loans to other entities		
1.12	Loans repaid by other entities		
1.13	Other (provide details if material)		
	Net investing cash flows	(91,749)	(91,749)
1.14	**Total operating and investing cash flows**	(1,641,390)	(1,641,390)
	Cash flows related to financing activities		
1.15	Proceeds from issues of shares, options, etc.	2,342,903	2,342,903
1.16	Proceeds from sale of forfeited shares		
1.17	Proceeds from borrowings		
1.18	Repayment of borrowings	(14,252)	(14,252)
1.19	Dividends paid		
1.20	Other (Payment of share capital raising costs))	(74,049)	(74,049)
	Net financing cash flows	2,254,602	2,254,602
	Net increase (decrease) in cash held	613,212	613,212
1.21	Cash at beginning of quarter/year to date	2,648,491	2,648,491
1.22	Exchange rate adjustments to item 1.20		
1.23	**Cash at end of quarter**	3,261,703	3,261,703

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities

		Current quarter $A
1.24	Aggregate amount of payments to the parties included in item 1.2	161,999
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

New Zealand directors (2) salaries & fees $39,413
US directors salary (1) $82,283
Australian directors fees (2) $11,869
UK directors salaries & fees (1) $28,434

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available $A	Amount used $A
3.1	Loan facilities		
3.2	Credit standby arrangements		

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter $A	Previous quarter $A
4.1	Cash on hand and at bank	3,079,763	2,464,671
4.2	Deposits at call	181,940	183,820
4.3	Bank overdraft		
4.4	Other (provide details)		
	Total: cash at end of quarter (item 1.22)	3,261,703	2,648,491

Acquisitions and disposals of business entities

		Acquisitions *(Item 1.9(a))*	Disposals *(Item 1.10(a))*
5.1	Name of entity	N/A	N/A
5.2	Place of incorporation or registration	N/A	N/A
5.3	Consideration for acquisition or disposal	N/A	N/A
5.4	Total net assets	N/A	N/A
5.5	Nature of business	N/A	N/A

Compliance statement

1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2 This statement does ~~/does not~~* *(delete one)* give a true and fair view of the matters disclosed.

Sign here: .... Date: ...27/10/2005...........
Company secretary)

Print name: N J V Geddes

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to

+ See chapter 19 for defined terms.

disclose additional information is encouraged to do so, in a note or notes attached to this report.

2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.

- 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
- 9.2 - itemised disclosure relating to acquisitions
- 9.4 - itemised disclosure relating to disposals
- 12.1(a) - policy for classification of cash items
- 12.3 - disclosure of restrictions on use of cash
- 13.1 - comparative information

3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.